S&P 500
(0.11%) 5 254.34 points
Dow J
(0.00%) 39 759 points
Nasdaq
(0.02%) 16 403 points
Oil
(1.57%) $82.63
Gas
(0.76%) $1.731
Gold
(1.99%) $2 234.20
Silver
(1.03%) $25.01
Platinum
(1.45%) $922.85
USD/EUR
(0.25%) $0.926
USD/NOK
(0.50%) $10.82
USD/GBP
(0.00%) $0.791
USD/RUB
(0.02%) $92.46

Realtime updates for Antisense Therapeutics [ANP.AX]

Exchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Last Updated2 Jan 2024 @ 23:56

-4.92% $ 0.0580

Live Chart Being Loaded With Signals

Commentary (2 Jan 2024 @ 23:56):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications...

Stats
Today's Volume 869 280
Average Volume 548 968
Market Cap 52.29M
EPS $0 ( 2024-02-19 )
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -2.90
ATR14 $0.00300 (5.36%)

Volume Correlation

Long: -0.22 (neutral)
Short: -0.74 (moderate negative)
Signal:(44.832) Neutral

Antisense Therapeutics Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Antisense Therapeutics Correlation - Currency/Commodity

The country flag -0.30
( neutral )
The country flag 0.17
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.64
( weak )

Antisense Therapeutics Financials

Annual 2022
Revenue: $1.58M
Gross Profit: $1.55M (97.91 %)
EPS: $-0.0179
Q4 2022
Revenue: $543 234
Gross Profit: $536 325 (98.73 %)
EPS: $-0.00460
Q3 2022
Revenue: $543 234
Gross Profit: $536 325 (98.73 %)
EPS: $-0.00460
Q2 2022
Revenue: $246 691
Gross Profit: $237 082 (96.10 %)
EPS: $-0.00390

Financial Reports:

No articles found.

Antisense Therapeutics

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators